The Persistent Sodium Current Blocker Riluzole Is Antiarrhythmic and Anti-Ischaemic in a Pig Model of Acute Myocardial Infarction by Weiss, Steven M. & Saint, David A.
The Persistent Sodium Current Blocker Riluzole Is
Antiarrhythmic and Anti-Ischaemic in a Pig Model of
Acute Myocardial Infarction
Steven M. Weiss
1, David A. Saint
2*
1Australian National University, Canberra, Australia, 2University of Adelaide, Adelaide, Australia
Abstract
Background: The potential of the cardiac persistent sodium current as a target for protection of the myocardium from
ischaemia and reperfusion injury is gaining increasing interest. We have investigated the anti-ischaemic and antiarrhythmic
effects of riluzole, a selective INaP blocker, in an open chest pig model of infarction.
Methods and Principal Findings: The left anterior descending coronary artery (LAD) was ligated in 27 anesthetised pigs
(landrace or large white, either sex, 20–35 kg) which had received riluzole (8 mg/kg IP; n=6), lidocaine (2.5–12 mg/kg bolus
plus 0.05–0.24 mg/kg/min; n=11) or vehicle (n=10) 50 min prior. Arrhythmias could be delineated into phase 1a (0 to
20 min), phase 1b (20 to 50 min) and phase 2 (from 50 min to termination at 180 min) and were classified as premature
ventricular contractions (PVCs), non-sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) (spontaneously
reverting within 15 s) or sustained VT or VF (ie. requiring cardioversion at 15 s). Riluzole reduced the average number of all
arrhythmias in Phase 2 (PVCs from 484+/2119 to 32+/213; non sustained arrhythmias from 8.9+/24.4 to 0.7+/20.5;
sustained arrhythmias from 3.9+/22.2 to 0.5+/20.4); lidocaine reduced the average number of non-sustained and sustained
arrhythmias (to 0.4+/20.3 and 0.4+/20.3 respectively) but not PVCs (to 390+/2234). Riluzole and lidocaine reduced the
average number of sustained arrhythmias in phase 1b (from 1.8+/20.4 to 0.17+/20.13 (p,0.02) and to 0.55+/20.26 (p=ns)
respectively). Neither lidocaine or riluzole changed the ECG intervals: there was no statistical significance between groups at
time zero (just before ligation) for any ECG measure. During the course of the 3 hour period of the ischaemia R-R, and P-R
intervals shortened slightly in control and riluzole groups (not significantly different from each other) but not in the
lidocaine group (significantly different from control). QRS and QTc did not change appreciably in any group Riluzole
reduced the degree of histopathological tissue damage across the infarct zone considerably more than did lidocaine.
Conclusions: At the doses used, riluzole was at least as effective as lidocaine at reducing the number of episodes of
ischaemic VT or VF in pigs, and much more effective at reducing the number of PVCs. We propose that this is related to the
ability of riluzole to block cardiac persistent sodium current.
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Introduction
Sudden cardiac death (SCD) as a consequence of ischaemic
arrhythmias is a major cause of mortality in the developed world,
and, importantly, ventricular fibrillation-related mortality appears
not to be declining despite a decline in the overall prevalence of
coronary artery disease (CAD) [1]. A therapeutic approach to
prevention of SCD would have a large impact on years of life lost.
However, large SCD trials of antiarrhythmic drugs have had
outcomes that have been either disappointing or, worse, showed
an increase in mortality in the treatment group [2]. A potential
novel target for cardiac ischaemic protection, the persistent
sodium current (INaP), has recently gained increasing interest
[3,4]. Here we report results with riluzole, a potentially new
cardiac protective agent which appears to act by blocking INaP,
and compare its effectiveness for suppression of ischaemic
arrhythmias with lidocaine.
Riluzole is currently approved for use in Man for amyotrophic
lateral sclerosis (ALS), and it has also been shown to be protective
against neuronal ischaemia in a variety of models [5,6,7]. This
action of riluzole is generally thought to be due to its ability to
block glutamate release and/or postsynaptic NMDA receptors
[8,9], although a variety of other mechanisms have been proposed,
including inhibition of neuronal sodium channels [10]. We have
recently shown that riluzole blocks the persistent sodium current
(INaP) in single cardiomyocytes, is cardioprotective in isolated rat
hearts, and prevents the rise in [Ca
2+]i induced in single myocytes
by hypoxia and reoxygenation, all with more than a 10-fold
greater potency than the block of the cardiac transient sodium
current (INaT) [11] In that paper we also showed that, under
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potential in isolated rat hearts or the ECG intervals in pigs. We
surmised that riluzole is protective against myocardial ischaemic
and reperfusion damage via its action to block INaP.
However, results in myocardial cells, or tissue preparations, or
small animal hearts, often do not predict effects on arrhythmogen-
esis in large animals, including man. In this study we were
interested in the potential of riluzole to reduce the occurrence
and/or severity of ischaemic arrhythmias (the leading clinical
cause of sudden cardiac death). We compared riluzole to an
established and well characterised drug, lidocaine. We show that
riluzole reduces the occurrence of ischaemic arrhythmias in an in
vivo pig model of acute myocardial infarction (AMI). We also show
that riluzole reduces the extent of myocardial damage at both the
gross and microscopic levels, and confirm that it has minimal
impact on normal ECG intervals in the pig AMI model. Riluzole
had greater anti-arrhythmic and anti-ischaemic potency than
lidocaine in this model. We conclude that riluzole may be
cardioprotective and antiarrhythmic in Phase 1b and Phase 2
ischaemia and possibly ischaemia-reperfusion settings, and that
riluzole is more potent than lidocaine in these settings. We further
suggest that these results shed light on the mechanisms underlying
different phases of ischaemic arrhythmias.
Methods
All procedures for these experiments had prior approval of the
Animal Experimentation and Ethics Committee of the Australian
National University: protocol numbers J.MB.38.08, J.MB.24.05,
J.MB.09.03. The investigation conforms to the Guide for the Care
and Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85–23, revised 1996).
All surgery was performed under anaesthesia, and all efforts were
made to minimise suffering.
27 pigs (landrace or large white, either sex, 20–35 kg) were
sedated with stresnil (Boehringer Ingelheim 1–2 mg/kg im) and
anaesthetized with thiopentone sodium (Troy Laboratories 10–
15 mg/kg iv) and isoflurane (Laser Animal Health 0.5 – 2%) in
oxygen. Artificial ventilation (Ugo Basile) was maintained at
15 ml/kg/breath and 12 breaths per minute. Blood pressure (BP)
and a lead II electrocardiogram (ECG) were monitored, digitised
and recorded (Data Translation) for subsequent analysis. An
intravenous normal saline drip was maintained for intra-operative
hydration (control group: 10 animals) or lidocaine (Troy
Laboratories) administration (lidocaine group: 11 animals, 2.5–
12 mg/kg bolus plus 0.05–0.24 mg/kg/min iv continuous infu-
sion). Riluzole (Sigma Pharmaceuticals) was administered intra-
peritoneally in 6 animals (riluzole group: 8 mg/kg in 2 ml
propylene glycol). Myocardial infarctions were created by ligating
the left anterior descending coronary arteries (LAD) mid-way
along their lengths approximately 50 min after the commence-
ment of saline, lidocaine or riluzole administration. Regional
ischaemia was confirmed by visual inspection for cyanosis and
dyskinetic wall motion [12]. Each experiment was terminated
3 hours after ligation.
Measurements of the overall length of each LAD and the
corresponding length of the ischaemic portion were made in each
animal to ensure that the extent of induced myocardial damage
was comparable between the control, lidocaine and riluzole
groups. Area at risk and the size of the infarcted zone were not
formally measured, although gross pathological changes were
assessed visually.
Data collection included counts of the number of premature
contractions, including PVCs and those in alternating rhythms
such as bigeminy and trigeminy, during the first three hours post
infarction. Data collection also included counts of the number of
runs of non-sustained arrhythmias (episodes of spontaneous
ventricular tachycardia (VT) or ventricular fibrillation (VF) lasting
for more than 1 s but self-terminating within 15 s of commence-
ment) and counts of the number of episodes of sustained VT or VF
(lasting for 15 s or more and requiring cardioversion or
defibrillation). Data analysis comprised comparing the number
of arrhythmias both by phase and by cumulative grouping.
Gross pathology was performed by a visual comparison of the
epicardial surface of each of the hearts in each of the groups post
fixation in 10% buffered formalin. Microscopic pathology was
performed by sampling full thickness sections of the myocardium
from the ligation site to the apex. Tissue was fixed in 10% neutral
buffered formalin and processed using routine laboratory methods
into wax blocks; sections were stained with hematoxylin and eosin
(H&E).
Statistical analysis was performed using Graphpad Prism.
Overall statistical significance was assessed using ANOVA,
followed by inter-group comparisons using t-tests if ANOVA
showed significance. Data is presented as mean +/2 SEM.
Significance was taken at p,0.05 and was determined using
Student’s t-tests.
Results
The positions of the ligations along the LAD, and hence the
proportions of ischaemic LAD to the overall length of the LAD,
averaged 52 +/21% in the control group, 59 +/22% in the
lidocaine group, and 57 +/22% in the riluzole group (not signi-
ficantly different).
Over the 3 hr post ligation period, all animals developed single
and multiple PVCs (doublets and triplets), though only 60% of
control animals, 45% of lidocaine animals and 33% of riluzole
animals developed bigeminy or trigeminy. While 90% of control
animals developed non-sustained VT or VF, only 36% of lidocaine
animals and 50% of riluzole animals did. While 100% of control
animals developed sustained VT or VF, only 55% of lidocaine
animals and 50% of riluzole animals did.
Figure 1 shows the average incidence of arrhythmias for all
animals across the PVC, non-sustained and sustained arrhythmia
classifications. Consistent with published data [13], there appeared
to be three distinct phases of high arrhythmia incidence: Phase 1a
arrhythmias occurred in the period from 0 to 20 minutes post
ligation, Phase 1b arrhythmias occurred in the period from 20 to
50 minutes post ligation, and Phase 2 occurred in the period from
50 to 180 minutes [14,15,16].
Compared with controls, riluzole significantly reduced the
incidence of all types of arrhythmias during Phase 2 (Figure 2, and
table 1). Riluzole also significantly reduced the incidence of
sustained arrhythmias during Phase 1b but did not reduce the
incidence of PVCs or non-sustained arrhythmias during Phase 1b
or any of the arrhythmias in Phase 1a. Compared with controls,
lidocaine significantly reduced the incidence of non-sustained and
sustained arrhythmias during Phase 2. In marked contrast to
riluzole, lidocaine did not reduce the incidence of PVCs in phase
2. While lidocaine did reduce the incidence of sustained
arrhythmias during Phase 1b, the reduction did not reach
statistical significance. Conversely, lidocaine appeared to increase
the incidence of non-sustained arrhythmias during phase 1b,
although this increase did not reach statistical significance.
Lidocaine did not reduce the incidence of PVCs during Phase
1b and did not reduce the incidence of any arrhythmia types
during Phase 1a.
Riluzole in Cardiac Ischaemia
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Cumulative data showed that for the first 45 minutes following
coronary artery ligation, there was a steady increase in the number
of PVCs in each of the control, lidocaine and riluzole groups.
However, during the 50 to 180 minute period post ligation, there
were very few PVCs in the riluzole group while the incidence of
PVCs in the control and lidocaine groups continued to rise steadily
(Figure 3a). The difference between the cumulative growth in the
number of PVCs in the control and riluzole groups was highly
significant, at p,0.00002. The difference between the control and
lidocaine groups was not significant.
Non-sustained arrhythmias
While the growth in the cumulative number of non-sustained
arrhythmias levelled off in both the lidocaine and riluzole groups
after 45 minutes post ligation, there were many non-sustained
arrhythmias in the 35 to 45 minute post ligation period in the
lidocaine group which caused there to be no significant difference
between the cumulative number of non-sustained arrhythmias in
the control and lidocaine groups (Figure 3b). In contrast, the
difference between the cumulative number of arrhythmias in the
control and riluzole groups was significant (p,0.01). The growth
in the cumulative number of non-sustained arrhythmias in the
riluzole group was about half that of the lidocaine group.
Sustained arrhythmias
The growth in the cumulative number of sustained arrhythmias
was significantly lower in both the lidocaine (p,0.00005) and
riluzole (p,0.00002) groups than in the control group (Figure 3c,
and table 1). As with the growth in the cumulative number of non-
sustained arrhythmias, the growth in the cumulative number of
sustained arrhythmias in the riluzole group was about half that of
the lidocaine group.
ECG intervals
ECG intervals were not significantly different between the
groups after drug administration and before ligation. During the
course of the 3 hour period of ischaemia R-R intervals shortened
slightly in control and riluzole treated animals (p ,0.001) but this
was not seen in the lidocaine treated animals. Similar results were
seen with P-R interval; a slight shortening in control and riluzole
treated animals which was not seen in the lidocaine group QRS
and QTc did not change appreciably during the course of the
3 hour ischaemia in any group. (figure 4)
Arrhythmogenesis
Most sustained and non-sustained arrhythmias were initiated by
an R-wave falling within the vulnerable period of the preceding T-
wave. Example traces are shown for a non-sustained arrhythmia in
figure 5A and for a sustained arrhythmia in figure 5B.
Histology
Gross examination of the hearts showed significant damage of
the anterior walls of both the left and right ventricular surfaces
extending from the ligation to the apex on all control hearts
(Figure 6A). In contrast, the hearts from the lidocaine group
showed smaller areas of damage towards the anterior apical region
of both ventricles (Figure 6B) while in the riluzole group, there was
minimal gross pathological damage evident (Figure 6C).
Microscopically, the anterior apical regions of the control hearts
showed extensive interstitial haemorrhage and oedema (Figure 6D
and 6E). In contrast, the anterior apical regions of the riluzole
hearts showed minimal oedema or haemorrhage (Figure 6F). The
extent of haemorrhage and oedema in the anterior apical region of
the lidocaine-treated hearts was more similar to that of the control
hearts (Figure 6G). Contraction band necrosis was most evident in
the control group. There was no inflammatory cell infiltrate.
Discussion
Phases of ischaemic arrhythmias
Reports of arrhythmias occurring in phases following an AMI
date back to 1950 [17]; the phases having been classified as Phase
1, associated with the period of reversible injury [1] and Phase 2,
which commences during the early inflammatory stage of infarct
evolution [18] and is defined by the establishment of myocardial
necrosis [1]. Further studies found that Phase 1 arrhythmias
comprised two distinct sub-classifications, now known as Phase 1a
and Phase 1b [14,19,20] with Phase 1b defined as heralding the
onset of irreversible myocardial damage [21]. Phase 1a arrhyth-
mias are generally considered to commence between 0 and 5
minutes post coronary artery occlusion [13,22,23] and terminate
between 3 and 20 minutes post occlusion [24,25,26]. Phase 1b
arrhythmias are generally defined as commencing between 5 and
20.5 minutes [13,16,27] and terminating between 18 and 90
minutes post occlusion [24,28,29,30]. Phase 2 arrhythmias
commence after phase 1b [16].
Consistent with this, in this study in in vivo pigs, we found that
Phase 1a spanned from 0 to 20 minutes, Phase 1b spanned from
20 to 50 minutes, and Phase 2 spanned from 50 to 180 minutes
(the time of termination of each experiment) after coronary artery
occlusion (figure 1). We also found that neither lidocaine nor
riluzole significantly affected the incidence of any of the types of
Phase 1a arrhythmias but that both reduced the incidence of
sustained arrhythmias during Phase 1b, although this was
significant at P,0.02 only for riluzole. Most notably, riluzole
significantly reduced the incidence of Phase 2 arrhythmias
irrespective of the type of arrhythmia (PVCs, doublets, triplets,
Figure 1. Time course of arrhythmias. Graphs of the average
number of arrhythmias per animal in each 5 minute time period over
the duration of each experiment for each of the three groups of
arrhythmias: PVCs (including single and multiple PVCs and alternating
rhythms such as bigeminy and trigeminy), non-sustained ventricular
tachycardia and ventricular fibrillation (lasting for more than 1 s but
self-terminating within 15 s of commencement), and sustained
ventricular tachycardia and ventricular fibrillation (lasting for more
than 15 s and requiring cardioversion or defibrillation). Note that the
number of PVCs shown is 1/10
th of the actual number of PVCs recorded
(to enable display on the same graph). The periods of peak arrhythmia
activity can be seen to extend between 0 and 20 mins, 20 and 50 mins,
and 50 and 180 mins, corresponding to Phase 1a, Phase 1b and Phase 2
arrhythmias respectively.
doi:10.1371/journal.pone.0014103.g001
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sustained VT and sustained VF).
Mechanism of action
We have previously shown that riluzole blocks myocardial INaP and
reduces the rise in intracellular [Ca
2+] resulting from hypoxia [31] and
we now show here that riluzole significantly reduces the extent of
myocardial damage at both the gross and microscopic levels following
3 hours of ischaemia. Similarly, it has been shown that lidocaine blocks
INaP [32] and intheseexperimentslidocaine alsoreduced the extent of
myocardial damage, although not as well as did riluzole. We therefore
propose that INaP blockers, and in particular riluzole, can reduce the
extent of myocardial damage as well as the incidence of Phase 2
arrhythmias and Phase 1b sustained arrhythmias.
Myocardial damage
Saint et al [33] showed that, under normal conditions, INaP
allows a Na
+ influx with an amplitude of around 0.5% of that of
Figure 2. Average number of arrhythmias by phase. Comparative graphs showing the average number of each arrhythmia type by phase for
the control, lidocaine and riluzole groups. Note that riluzole and lidocaine significantly reduced the number of Phase 2 non-sustained and sustained
arrhythmias. Note also that riluzole and lidocaine reduced the number of Phase 1b sustained arrhythmias but that this was not significant for
lidocaine. In addition, riluzole significantly reduced the number of Phase 2 PVCs whereas lidocaine had minimal effect.
doi:10.1371/journal.pone.0014103.g002
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such as ischaemia, INaP is enhanced by about a factor of 3 or 4
[34]. Because INaP does not inactivate, it can potentially cause a
large influx of Na
+ and the consequent rise in [Na
+]i can produce
a slowing or reversal of the myocardial sodium-calcium exchanger
(NCX) [35]. The subsequent overloading of cells with Ca
2+ causes
Table 1. Average number of arrhythmias per animal for each group in each of the phases. ‘‘n’’ refers to the number of animals in
each group.
CONTROL (n=10) LIDOCAINE (n=11) RILUZOLE (n=6)
mean SEM mean SEM mean SEM
PVCs Phase 1a
0–20 mins
38.90 15.57 53.00 28.68 49.33 21.11
Phase 1b
20–50 mins
134.10 39.08 102.45 50.96 148.67 31.84
Phase 2
50–180 mins
484.60 199.86 390.09 234.09 32.50 13.32
TOTAL 657.60 190.19 545.55 278.73 230.50 78.96
Non-sustained
arrhythmias
Phase 1a
0–20 mins
0.40 0.31 1.09 0.54 0.17 0.13
Phase 1b
20–50 mins
3.20 1.74 4.82 3.55 2.33 1.24
Phase 2
50–180 mins
8.90 4.41 0.45 0.33 0.67 0.52
TOTAL 12.50 4.15 6.36 3.77 3.17 2.26
Sustained
arrhythmias
Phase 1a
0–20 mins
0.40 0.27 0.27 0.20 0.17 0.13
Phase 1b
20–50 mins
1.80 0.44 0.55 0.26 0.17 0.13
Phase 2
50–180 mins
3.90 2.21 0.36 0.29 0.50 0.39
TOTAL 6.10 2.61 1.18 0.40 0.83 0.48
doi:10.1371/journal.pone.0014103.t001
Figure 3. Cumulative incidence of arrhythmias. Comparative graphs showing reductions in the cumulative average number of arrhythmias per
animal by arrhythmia types for control, lidocaine and riluzole groups of animals. Note the significant reduction in the number of each type of
arrhythmia by riluzole as compared with lidocaine and control (note different scales on y axes).
doi:10.1371/journal.pone.0014103.g003
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coupling [36]. Hence, it appears that lidocaine and riluzole, both
myocardial INaP blockers, significantly reduced the extent of
myocardial damage from ischaemia by reducing the [Na
+]i
overload and consequent sequence of events leading to [Ca
2+]i
loading and cell damage.
Arrhythmias
There are three potential mechanisms by which arrhythmias
can be maintained in ventricular myocardium - re-entrant,
triggered activity, and abnormal automaticity. Re-entrant ar-
rhythmias require unidirectional conduction, conduction block,
and a region of slow conduction such that the cycle length of the
arrhythmia is longer than the longest refractory period in the
circuit [37]. All these factors can result from myocardial damage
and in particular the loss of gap junctions, impaired cell coupling
and myocardial heterogeneity which occur during Phase 1b and
Phase 2 [36]. Therefore, given the coincident timing of Phase 1b
and Phase 2 arrhythmias seen in this study with the development
of myocardial damage and the substrate required for re-entrant
arrhythmias, it would appear that riluzole and lidocaine reduced
Figure 4. Time course of ECG intervals. P l o t so fR - R ,P - R ,Q R Sa n dQ T ci n t e r v a l sd u r i n gt h ee x p e r i m e n t .D a t aa r es h o w nf o r3 0 ,6 0 ,9 0 ,1 2 0 ,1 5 0a n d
180 min after ligation (points are displaced for clarity). Symbols show mean +/2SEM. Control = filled circles, riluzole = filled squares, lidocaine = filled triangles.
doi:10.1371/journal.pone.0014103.g004
Figure 5. PVC-initiation of arrhythmias. Panel A shows a PVC
initiated self-terminating ventricular tachycardia while panel B shows a
PVC-initiated ventricular fibrillation. The arrows show the arrhythmia-
initiating PVCs falling on the previous T-wave.
doi:10.1371/journal.pone.0014103.g005
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PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e14103Figure 6. Pathologic changes. Upper panels: Examples of the gross pathologic damage in the control (panel A), lidocaine (panel B) and riluzole
(panel C) groups. Note the shadow representative of the border zone in the lidocaine group and the minimal damage in the riluzole group. Lower
panels: Examples of microscopic myocardial damage. Panel D shows haemorrhage and oedema in a control heart at low magnification. Panel E shows
extensive oedema in a control heart at high magnification. Panel F shows minimal haemorrhage or oedema in a riluzole heart at high magnification.
Panel G shows moderate oedema in a lidocaine heart at low magnification.
doi:10.1371/journal.pone.0014103.g006
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doing, reduced the damage to an amount too small and/or too
homogenous to sustain re-entrant arrhythmias. It appears that
riluzole is more potent than lidocaine in reducing myocardial
damage and the incidence of re-entrant arrhythmias, possibly
because the selectivity for block of INaP over INaT is higher for
riluzole than for lidocaine. Alternatively, given that lidocaine was
less effective in reducing myocardial damage than riluzole, its
effect to reduce arrhythmias may have been due to its class Ib
action.
While re-entrant arrhythmias require a suitable substrate in
order to be sustained, they also require a stimulus for initiation. As
exemplified in Figures 5A and 5B, many of the non-sustained and
sustained arrhythmias were initiated by single PVCs falling in the
middle of the preceding T-wave; this portion of the T-wave
corresponding to the vulnerable period for R-on-T initiation of
arrhythmias [38,39]. While there is the possibility that arrhythmias
in this study were initiated by an automatic focus, the coincident
timing with the T-wave makes this outcome unlikely and it is far
more likely that most of the arrhythmias in this study were
initiated by EADs.
We note some potentially important differences between
lidocaine and riluzole. 1. Riluzole blocked PVCs during phase 2,
whereas lidocaine did not. We suggest that this indicates that
riluzole is more effective at preventing the calcium overload
contributing to DADs. 2. There was a trend for lidocaine to be
proarrhythmic for non-sustained arrhythmias during Phase 1b.
This may indicate that lidocaine at this time is exacerbating
electrical heterogeneity because of its effects on conduction
velocity and threshold, via block of INaT, while riluzole does
not produce these effects. 3. Riluzole did not change the ECG
intervals before ligation at anti-arrhythmic doses and did not affect
the ECG intervals during the 3 hour period of ischaemia. We
suggest that these differences are due to the more selective block of
INaP over INaT by riluzole, as compared to lidocaine. Our results
suggest that the Phase 2 arrhythmias and the Phase 1b sustained
arrhythmias observed in this study were re-entrant arrhythmias
initiated by triggered activity which was DAD driven. We
hypothesise that, by blocking myocardial INaP, riluzole and
lidocaine reduced the rise in intracellular [Ca
2+] required to cause
triggered activity and in so-doing, reduced the stimulus for
initiating the Phase 2 arrhythmias and the Phase 1b non-sustained
arrhythmias as well as the size of the substrate required for the
maintenance of re-entrant arrhythmias. We further propose that
riluzole was more effective than lidocaine in reducing the extent of
myocardial damage and the incidence of Phase 2 PVCs and Phase
1b non-sustained arrhythmias because of their different actions on
cardiomyocytes and conduction.
The results demonstrate a potent effect of riluzole against
ischaemia-induced arrhythmias and ischaemic damage. We
suggest that these actions are due to action at a potential novel
target, the cardiac persistent sodium current.
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